Piramal Pharma Limited has reported consolidated financial results for the period ended March 31, 2025.

Piramal Pharma has posted net profit of Rs. 153.50 crores for the period ended March 31, 2025 as against net profit of Rs. 3.68 crores for the period ended December 31, 2024.  The company posted net profit of Rs. 101.27 crores for the period ended March 31, 2024.

Piramal Pharma has reported total income of Rs. 2,796.10 crores during the period ended March 31, 2025 as compared to Rs. 2,216.35 crores during the period ended December 31, 2024. The company reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024.

For the Financial Year ended March 31, 2025, Piramal Pharma has reported total income of Rs. 9,285.99 crores as compared to Rs. 8,346.55 crores during the Financial Year ended March 31, 2024.

The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025 as against net profit of Rs. 17.82 crores for the Financial Year ended March 31, 2024.

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY25 has been a steady year for the company as we crossed $1Bn in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth. During the year, weprogressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business.

We believe, we are on track to deliver on our FY2030 aspirations of becoming a $2bn revenue company with 25% EBITDA margins and high teens ROCE.”